[Clinical evaluation of the hypotensive effectiveness of Betoptic preparation]

Clinical trials of the hypotensive effect of 0.5% betoptic, an antiglaucoma drug manufactured by Alcon (USA), were carried out at three ophthalmologic hospitals. Similar results obtained in all the trials permit a conclusion on a high hypotensive efficacy of this drug in patients with primary open-angle glaucoma. The drug was well tolerated by the patients.